WCA
XLRN

Windsor Creek Advisors’s Acceleron Pharma XLRN Stock Holding History

Windsor Creek Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,000
Closed -$205K – 197
2019
Q2 		$205K Buy
+5,000
New +$207K 0.06% 150

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Windsor Creek Advisors's XLRN Position: Q3 2019 in Review

Windsor Creek Advisors sold out of Acceleron Pharma (XLRN) in Q3 2019, closing a stake of 5,000 shares — an estimated $205K sold.

Windsor Creek Advisors first reported a position in XLRN in Q2 2019 and held it in 1 quarter. The position peaked at $205K in Q2 2019. 172 funds tracked by Wall St. Rank hold XLRN as of Q3 2019.

  • Windsor Creek Advisors reported no remaining Acceleron Pharma position as of Q3 2019 after selling out during the quarter.
  • Windsor Creek Advisors sold 5,000 Acceleron Pharma shares in Q3 2019, an estimated $205K.
  • Windsor Creek Advisors first reported a position in Acceleron Pharma in Q2 2019 and held it in 1 quarter.
  • Windsor Creek Advisors's Acceleron Pharma position peaked at $205K in Q2 2019.
  • 172 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2019.

Based on Windsor Creek Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.